首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1734250

转移性大肠直肠癌市场（按药物类别和地区）分析与预测（2025-2035）

Global Metastatic Colorectal Cancer Market: Focus on Drug Class, and Region - Analysis and Forecast, 2025-2035

出版日期: 2025年05月28日 | 出版商:

BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

简介目录图表

全球转移性大肠直肠癌 (mCRC) 市场是肿瘤製药行业的一个重要领域，其发展受到结直肠癌发病率上升、治疗技术的进步以及对改善患者预后的日益关注的推动。

转移性大肠直肠癌是起源于结肠或直肠并扩散至肝臟或肺等远端器官的癌症。 mCRC 是一种复杂且侵袭性的癌症，通常预后不良且治疗选择有限。因此，mCRC 市场对有效治疗方法不仅可以控制疾病，还可以延长生存期并改善患者的生活品质。

标靶治疗的引入是转移性大肠直肠癌市场最重大的进步之一。Bevacizumab（Avastin）和Cetuximab（Erbitux）等药物已被开发用于特异性针对与癌细胞生长和转移有关的分子通路，与传统化疗相比，它们提供了更有效的治疗选择，且副作用更少。这些治疗方法通常与化疗相结合，以提高疗效，特别是在疾病广泛扩散的情况下。此外，针对特定突变的新型单株抗体和小分子抑制剂，如表皮生长因子受体（EGFR）抑制剂和血管内皮生长因子（VEGF）抑制剂，具有进一步先进的治疗选择。

mCRC 治疗中最令人兴奋的进展之一是免疫疗法的出现。免疫疗法是治疗方法。免疫查核点抑制剂，如Pembrolizumab(Keytruda) 和Nivolumab(Opdivo )，已对某些 mCRC 患者表现出显着疗效，尤其是那些微卫星不稳定性高 (MSI-H) 或错配修復缺陷 (dMMR) 肿瘤患者。这些患者是 mCRC 患者的一个子集，由于免疫查核点抑制剂重新运作人体对癌症的免疫反应，他们的整体存活期和无恶化生存期存活期可以显着改善。

除了这些治疗方法之外，转移性大肠直肠癌市场越来越关注联合治疗结合不同类别的多种药物以最大限度地提高治疗效果。例如，化疗与标靶治疗和免疫治疗相结合在临床试验中已显示出良好的效果，可延长晚期疾病患者的生存期并提高其生活品质。

个人化医疗的兴起也是转移性大肠直肠癌市场的关键趋势。基因序列测定和生物标记识别的进步使肿瘤学家能够根据患者肿瘤的特征制定治疗方案，确保更精确、更有效的治疗。个人化医疗也促进了分子诊断的使用，帮助选择最有可能受益于特定治疗的患者，优化治疗结果并最大限度地减少不必要的副作用。

全球转移性大肠直肠癌市场具有高度创新的特点，多家製药和生物技术公司积极致力于开发新的治疗方法。这些公司拥有广泛的开发平臺，其中许多公司正在从事临床试验，旨在发现新的分子标靶和创新药物配方，以改善 mCRC 的治疗。

此外，专注于免疫疗法和新型药物输送系统的新兴生物技术公司正越来越多地进入转移性大肠直肠癌市场。这些公司通常处于新科学发展的前沿，致力于透过开发针对该疾病特定分子亚型的标靶治疗来解决转移性结直肠癌治疗中未满足的需求，为未来更有效的治疗带来希望。

影响

预计转移性大肠直肠癌需求的不断增长将在 2025-2035 年预测期内支持全球转移性大肠直肠癌市场的成长。
由于药物开发的持续进步，包括标靶治疗和个人化医疗，预计市场将以显着的速度成长，这为引入治疗转移性结直肠癌的新疗法提供了巨大的机会。

根据地区来看，转移性大肠直肠癌市场在所有地区都经历显着的成长。北美继续成为转移性大肠直肠癌治疗的最大市场，这得益于其高盛行率、发达的医疗保健基础设施以及主要企业的存在。美国是一个关键市场，拥有先进的医疗保健和尖端癌症治疗方法，而欧洲也是一个关键市场，因为该地区拥有高标准的医疗保健和不断增加的癌症研究投资。由于确诊病例数增加、认识度提高以及医疗保健可近性的改善，预计亚太地区将在未来几年内出现最高增长，尤其是在中国和印度等国家。

本报告研究了全球转移性大肠直肠癌市场，概述了市场状况以及药物类别、地区和参与市场的公司概况的趋势。

竞争格局
- 关键发展和策略
公司简介
- Amgen Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Sanofi
- Merck KGaA
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Taiho Oncology
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Shanghai Henlius Biotech
- Inspirna
- Treos Bio

第五章调查方法

简介目录图表

Product Code: BHL2877SA

Global Metastatic Colorectal Cancer Market, Analysis and Forecast: 2025-2035

The global metastatic colorectal cancer (mCRC) market represents a critical segment within the oncology pharmaceutical industry, driven by the increasing incidence of colorectal cancer, advancements in therapeutic technologies, and a growing emphasis on improving patient outcomes. Metastatic colorectal cancer refers to a stage of colorectal cancer where the disease has spread from the original site in the colon or rectum to other parts of the body, often the liver, lungs, or other distant organs. It is a complex and aggressive form of cancer, typically associated with poor prognosis and limited treatment options. As a result, the mCRC market is characterized by high demand for effective therapies that can not only manage the disease but also extend survival and improve the quality of life for patients.

The introduction of targeted therapies has been one of the most significant advancements in the metastatic colorectal cancer market. Drugs such as bevacizumab (Avastin) and cetuximab (Erbitux) have been developed to specifically target the molecular pathways involved in cancer cell growth and metastasis, offering more effective treatment options with fewer side effects compared to traditional chemotherapy. These therapies are often used in combination with chemotherapy to improve efficacy, particularly in cases where the disease has spread extensively. Additionally, newer monoclonal antibodies and small molecule inhibitors targeting specific mutations, such as epidermal growth factor receptor (EGFR) inhibitors and vascular endothelial growth factor (VEGF) inhibitors, have further advanced treatment options.

One of the most transformative developments in the treatment of mCRC has been the advent of immunotherapy. Immunotherapy represents a class of treatments that harness the body's immune system to recognize and attack cancer cells. Immune checkpoint inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), have demonstrated impressive efficacy in certain mCRC patients, particularly those with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. These patients, who represent a subset of the mCRC population, can experience significant improvements in overall survival and progression-free survival due to the ability of immune checkpoint inhibitors to reactivate the body's immune response against the cancer.

In addition to these treatment, the metastatic colorectal cancer market is witnessing a growing focus on combination therapies, where multiple drugs from different classes are used in tandem to maximize treatment efficacy. For instance, combining chemotherapy with targeted therapies or immunotherapies has shown promising results in clinical trials, leading to longer survival times and improved quality of life for patients with advanced disease.

The emergence of personalized medicine is another pivotal trend within the metastatic colorectal cancer market. With advancements in genomic sequencing and biomarker identification, oncologists can now tailor treatments to the individual characteristics of a patient's tumor, ensuring more precise and effective therapies. Personalized medicine also facilitates the use of molecular diagnostics, which help in selecting patients who are most likely to benefit from specific therapies, thus optimizing treatment outcomes and minimizing unnecessary side effects.

The global metastatic colorectal cancer market is characterized by a high level of innovation, with several pharmaceutical companies and biotechnology firms actively involved in the development of novel therapies. The companies have large R&D pipelines, and many of them are engaged in clinical trials aimed at discovering new molecular targets and innovative drug formulations to improve mCRC treatment.

Additionally, emerging biotech companies focusing on immunotherapy and novel drug delivery systems are increasingly entering the metastatic colorectal cancer market. These companies are often at the forefront of new scientific developments, seeking to address the unmet needs in the treatment of metastatic colorectal cancer by developing targeted therapies for specific molecular subtypes of the disease, offering hope for more effective treatments in the future.

Impact

Increasing demand for metastatic colorectal cancer is anticipated to support the growth of the global metastatic colorectal cancer market during the forecast period 2025-2035.
The market is expected to grow at a significant growth rate due to opportunities such as the Continued advancements in drug development, including targeted therapies and personalized medicine, offer significant opportunities for the introduction of novel therapies for metastatic colorectal cancer treatment.

Market Segmentation:

Segmentation 1: by Drug Class

Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors
Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
Immune Checkpoint Inhibitors
Others

Segmentation 2: by Region

North America
Europe
Asia-Pacific

Geographically, the metastatic colorectal cancer market is witnessing substantial growth across all regions. North America remains the largest market for mCRC therapies, driven by the high prevalence of the disease, significant healthcare infrastructure, and the presence of leading pharmaceutical companies. The U.S. is a key market, with access to advanced healthcare and cutting-edge cancer treatments, while Europe also represents a significant market due to the high standards of healthcare in the region and increasing investments in oncology research. Asia-Pacific is expected to experience the highest growth in the coming years, driven by the increasing number of diagnosed cases, rising awareness, and improved healthcare access, particularly in countries like China and India.

Executive Summary

Scope and Definition

Market/Product Definition

Key Questions Answered

Analysis and Forecast Note

1. Global Metastatic Colorectal Cancer Market: Industry Outlook

1.1 Market Overview
1.2 Epidemiological Analysis of Metastatic Colorectal Cancer
- 1.2.1 By Region
1.3 Regulatory Landscape of Global Metastatic Colorectal Cancer Market
- 1.3.1 Legal Requirement and Framework in the U.S.
- 1.3.2 Legal Requirement and Framework in the E.U.
1.4 Key Trends
1.5 Clinical Trial Analysis
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Restraint
- 1.6.4 Market Opportunities

2. Global Metastatic Colorectal Cancer Market, by Drug Class, $Million, 2023-2035

2.1 Overview
2.2 Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors
2.3 Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
2.4 Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
2.5 Immune Checkpoint Inhibitors
2.6 Others

3. Global Metastatic Colorectal Cancer Market, by Region, $Million, 2023-2035

3.1 North America
- 3.1.1 Key Market Participants in North America
- 3.1.2 Business Drivers
- 3.1.3 Business Challenges
- 3.1.4 Market Sizing and Forecast
  - 3.1.4.1 North America Metastatic Colorectal Cancer Market, by Country
    - 3.1.4.1.1 U.S.
3.2 Europe
- 3.2.1 Key Market Participants in Europe
- 3.2.2 Business Drivers
- 3.2.3 Business Challenges
  - 3.2.3.1 Europe Metastatic Colorectal Cancer Market, by Country
    - 3.2.3.1.1 Germany
    - 3.2.3.1.2 U.K.
    - 3.2.3.1.3 France
    - 3.2.3.1.4 Italy
    - 3.2.3.1.5 Spain
3.3 Asia-Pacific
- 3.3.1 Key Market Participants in Asia-Pacific
- 3.3.2 Business Drivers
- 3.3.3 Business Challenges
  - 3.3.3.1 Asia-Pacific Metastatic Colorectal Cancer Market, by Country
    - 3.3.3.1.1 Japan

4. Global Metastatic Colorectal Cancer Market: Competitive Landscape and Company Profiles

4.1 Competitive Landscape
- 4.1.1 Key Developments and Strategies
  - 4.1.1.1 Funding Activities
  - 4.1.1.2 Mergers and Acquisitions
  - 4.1.1.3 Regulatory Approvals
  - 4.1.1.4 Partnerships, Collaborations and Business Expansions
4.2 Company Profiles
- 4.2.1 Amgen Inc.
  - 4.2.1.1 Overview
  - 4.2.1.2 Product Portfolio
  - 4.2.1.3 Target Customers
  - 4.2.1.4 Key Professionals
  - 4.2.1.5 Analyst View
- 4.2.2 Pfizer Inc.
  - 4.2.2.1 Overview
  - 4.2.2.2 Product Portfolio
  - 4.2.2.3 Target Customers
  - 4.2.2.4 Key Professionals
  - 4.2.2.5 Analyst View
- 4.2.3 Eli Lilly and Company
  - 4.2.3.1 Overview
  - 4.2.3.2 Product Portfolio
  - 4.2.3.3 Target Customers
  - 4.2.3.4 Key Professionals
  - 4.2.3.5 Analyst View
- 4.2.4 Sanofi
  - 4.2.4.1 Overview
  - 4.2.4.2 Product Portfolio
  - 4.2.4.3 Target Customers
  - 4.2.4.4 Key Professionals
  - 4.2.4.5 Analyst View
- 4.2.5 Merck KGaA
  - 4.2.5.1 Overview
  - 4.2.5.2 Product Portfolio
  - 4.2.5.3 Target Customers
  - 4.2.5.4 Key Professionals
  - 4.2.5.5 Analyst View
- 4.2.6 Novartis AG
  - 4.2.6.1 Overview
  - 4.2.6.2 Product Portfolio
  - 4.2.6.3 Target Customers
  - 4.2.6.4 Key Professionals
  - 4.2.6.5 Analyst View
- 4.2.7 Takeda Pharmaceutical Company Limited
  - 4.2.7.1 Overview
  - 4.2.7.2 Product Portfolio
  - 4.2.7.3 Target Customers
  - 4.2.7.4 Key Professionals
  - 4.2.7.5 Analyst View
- 4.2.8 Taiho Oncology
  - 4.2.8.1 Overview
  - 4.2.8.2 Product Portfolio
  - 4.2.8.3 Target Customers
  - 4.2.8.4 Key Professionals
  - 4.2.8.5 Analyst View
- 4.2.9 Bristol-Myers Squibb Company
  - 4.2.9.1 Overview
  - 4.2.9.2 Product Portfolio
  - 4.2.9.3 Target Customers
  - 4.2.9.4 Key Professionals
  - 4.2.9.5 Analyst View
- 4.2.10 Johnson & Johnson Services, Inc.
  - 4.2.10.1 Overview
  - 4.2.10.2 Product Portfolio
  - 4.2.10.3 Target Customers
  - 4.2.10.4 Key Professionals
  - 4.2.10.5 Analyst View
- 4.2.11 Shanghai Henlius Biotech
  - 4.2.11.1 Overview
  - 4.2.11.2 Product Portfolio
  - 4.2.11.3 Target Customers
  - 4.2.11.4 Key Professionals
  - 4.2.11.5 Analyst View
- 4.2.12 Inspirna
  - 4.2.12.1 Overview
  - 4.2.12.2 Product Portfolio
  - 4.2.12.3 Target Customers
  - 4.2.12.4 Key Professionals
  - 4.2.12.5 Analyst View
- 4.2.13 Treos Bio
  - 4.2.13.1 Overview
  - 4.2.13.2 Product Portfolio
  - 4.2.13.3 Target Customers
  - 4.2.13.4 Key Professionals
  - 4.2.13.5 Analyst View

5. Research Methodology

简介目录图表

List of Figures

Figure: Global Metastatic Colorectal Cancer Market, Market Overview
Figure: Global Metastatic Colorectal Cancer Market, Epidemiological Analysis
Figure: Global Metastatic Colorectal Cancer Market Coverage
Figure: Global Metastatic Colorectal Cancer Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Metastatic Colorectal Cancer Market, Competitive Landscape, January 2022-April 2025